-
Je něco špatně v tomto záznamu ?
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary
Y. Handelsman, PS. Jellinger, CK. Guerin, ZT. Bloomgarden, EA. Brinton, MJ. Budoff, MH. Davidson, D. Einhorn, S. Fazio, VA. Fonseca, AJ. Garber, G. Grunberger, RM. Krauss, JI. Mechanick, PD. Rosenblit, DA. Smith, KL. Wyne
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1995-01-01 do 2020-12-31
Nursing & Allied Health Database (ProQuest)
od 1995-01-01 do 2020-12-31
Health & Medicine (ProQuest)
od 1995-01-01 do 2020-12-31
Family Health Database (ProQuest)
od 1995-01-01 do 2020-12-31
Health Management Database (ProQuest)
od 1995-01-01 do 2020-12-31
PubMed
33471721
DOI
10.4158/cs-2020-0490
Knihovny.cz E-zdroje
- MeSH
- algoritmy MeSH
- anticholesteremika * MeSH
- dyslipidemie * farmakoterapie epidemiologie MeSH
- endokrinologové MeSH
- kardiovaskulární nemoci * epidemiologie prevence a kontrola MeSH
- konsensus MeSH
- lidé MeSH
- rizikové faktory MeSH
- statiny * terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Spojené státy americké MeSH
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a) and statin intolerance is also described.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012065
- 003
- CZ-PrNML
- 005
- 20210507102043.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4158/CS-2020-0490 $2 doi
- 035 __
- $a (PubMed)33471721
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Handelsman, Yehuda $u Medical Director & Principal Investigator, Metabolic Institute of America, Tarzana, California. Electronic address: yhandelsman@gmail.com
- 245 10
- $a Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary / $c Y. Handelsman, PS. Jellinger, CK. Guerin, ZT. Bloomgarden, EA. Brinton, MJ. Budoff, MH. Davidson, D. Einhorn, S. Fazio, VA. Fonseca, AJ. Garber, G. Grunberger, RM. Krauss, JI. Mechanick, PD. Rosenblit, DA. Smith, KL. Wyne
- 520 9_
- $a The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a) and statin intolerance is also described.
- 650 _2
- $a algoritmy $7 D000465
- 650 12
- $a anticholesteremika $7 D000924
- 650 12
- $a kardiovaskulární nemoci $x epidemiologie $x prevence a kontrola $7 D002318
- 650 _2
- $a konsensus $7 D032921
- 650 12
- $a dyslipidemie $x farmakoterapie $x epidemiologie $7 D050171
- 650 _2
- $a endokrinologové $7 D000072097
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a rizikové faktory $7 D012307
- 651 _2
- $a Spojené státy americké $7 D014481
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jellinger, Paul S $u Professor of Clinical Medicine, Voluntary Faculty, University of Miami Miller School of Medicine, Center for Diabetes & Endocrine Care, Hollywood, Florida
- 700 1_
- $a Guerin, Chris K $u Clinical Assistant Professor of Medicine, Voluntary Faculty, University of California San Diego, San Diego, California
- 700 1_
- $a Bloomgarden, Zachary T $u Editor, the Journal of Diabetes, Clinical Professor, Icahn School of Medicine at Mount Sinai, New York, New York
- 700 1_
- $a Brinton, Eliot A $u President, Utah Lipid Center, Salt Lake City, Utah, Past President, American Board of Clinical Lipidology, Torrance, California
- 700 1_
- $a Budoff, Matthew J $u Professor of Medicine, UCLA Endowed Chair of Preventive Cardiology, Los Angeles Biomedical Research Institute, Torrance, California
- 700 1_
- $a Davidson, Michael H $u Professor, Director of the Lipid Clinic, University of Chicago Pritzker School of Medicine, Chicago, Illinois
- 700 1_
- $a Einhorn, Daniel $u Associate Editor, the Journal of Diabetes, Medical Director, Scripps Whittier Diabetes Institute, Clinical Professor of Medicine, UCSD, President, Diabetes and Endocrine Associates, San Diego, California
- 700 1_
- $a Fazio, Sergio $u The William and Sonja Connor Chair of Preventive Cardiology, Professor of Medicine and Physiology & Pharmacology, Director, Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon
- 700 1_
- $a Fonseca, Vivian A $u Professor of Medicine and Pharmacology, Assistant Dean for Clinical Research, Tullis Tulane Alumni Chair in Diabetes, Chief, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana
- 700 1_
- $a Garber, Alan J $u Professor, Departments of Medicine, Biochemistry and Cell and Molecular Biology, Baylor College of Medicine, Houston, Texas
- 700 1_
- $a Grunberger, George $u Chairman, Grunberger Diabetes Institute, Clinical Professor, Internal Medicine and Molecular Medicine & Genetics, Wayne State University School of Medicine, Professor, Internal Medicine, Oakland University William Beaumont School of Medicine, Visiting Professor, Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic, Past President, American Association of Clinical Endocrinologists, Bloomfield Hills, Michigan
- 700 1_
- $a Krauss, Ronald M $u Professor of Pediatrics and Medicine, UCSF, Adjunct Professor, Department of Nutritional Sciences, University of California, Berkeley, Dolores Jordan Endowed Chair, UCSF Benioff Children's Hospital Oakland, New York, New York
- 700 1_
- $a Mechanick, Jeffrey I $u Professor of Medicine, Medical Director, The Marie-Josee and Henry R. Kravis Center for Clinical Cardiovascular Health at Mount Sinai Heart, Director, Metabolic Support, Divisions of Cardiology and Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai Heart, Director, Metabolic Support, Divisions of Cardiology and Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York
- 700 1_
- $a Rosenblit, Paul D $u Clinical Professor, Medicine (Division of Endocrinology, Diabetes, Metabolism), University California, Irvine, School of Medicine, Irvine, California, Co-Director, Diabetes Out-Patient Clinic, UCI Medical Center, Orange, California, Director & Site Principal Investigator, Diabetes/Lipid Management & Research Center, Huntington Beach, California
- 700 1_
- $a Smith, Donald A $u Endocrinologist, Clinical Lipidologist, Associate Professor of Medicine, Icahn School of Medicine Mount Sinai, Director Lipids and Metabolism, Mount Sinai Heart, New York, New York
- 700 1_
- $a Wyne, Kathleen L $u Director, Adult Type 1 Diabetes Program, Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Wexner Medical Center, Columbus, Ohio
- 773 0_
- $w MED00207059 $t Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists $x 1530-891X $g Roč. 26, č. 10 (2020), s. 1196-1224
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33471721 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507102043 $b ABA008
- 999 __
- $a ok $b bmc $g 1650445 $s 1132444
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 26 $c 10 $d 1196-1224 $e - $i 1530-891X $m Endocrine practice $n Endocr Pract $x MED00207059
- LZP __
- $a Pubmed-20210420